Medidata Solutions (NASDAQ:MDSO) was downgraded by equities researchers at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a report released on Wednesday, The Fly reports.
Several other research analysts also recently commented on the company. SunTrust Banks downgraded Medidata Solutions from a “buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research report on Wednesday, April 24th. William Blair started coverage on Medidata Solutions in a research report on Monday, April 15th. They issued an “outperform” rating and a $74.93 price target on the stock. TheStreet raised Medidata Solutions from a “c+” rating to a “b-” rating in a research report on Friday, March 15th. Wells Fargo & Co downgraded Medidata Solutions from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research report on Tuesday, April 23rd. Finally, Dougherty & Co downgraded Medidata Solutions from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $84.24.
NASDAQ MDSO traded down $3.38 during trading on Wednesday, hitting $91.37. The company’s stock had a trading volume of 466,435 shares, compared to its average volume of 702,774. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.29. The company has a market cap of $5.90 billion, a P/E ratio of 95.14, a P/E/G ratio of 8.43 and a beta of 1.31. Medidata Solutions has a 52 week low of $60.10 and a 52 week high of $98.60.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.33. The company had revenue of $173.50 million for the quarter, compared to the consensus estimate of $172.12 million. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. The company’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.40 EPS. Sell-side analysts expect that Medidata Solutions will post 0.79 earnings per share for the current fiscal year.
In related news, Director Robert Taylor sold 3,294 shares of the business’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total value of $299,358.72. Following the sale, the director now owns 41,757 shares of the company’s stock, valued at approximately $3,794,876.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.70% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Alps Advisors Inc. boosted its stake in Medidata Solutions by 0.3% in the second quarter. Alps Advisors Inc. now owns 8,430 shares of the company’s stock worth $659,000 after purchasing an additional 22 shares in the last quarter. 1st Global Advisors Inc. boosted its stake in Medidata Solutions by 0.5% in the second quarter. 1st Global Advisors Inc. now owns 8,243 shares of the company’s stock worth $645,000 after purchasing an additional 37 shares in the last quarter. World Asset Management Inc boosted its stake in Medidata Solutions by 1.2% in the second quarter. World Asset Management Inc now owns 3,528 shares of the company’s stock worth $276,000 after purchasing an additional 43 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Medidata Solutions by 0.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 33,828 shares of the company’s stock worth $2,645,000 after purchasing an additional 109 shares in the last quarter. Finally, Securian Asset Management Inc boosted its stake in Medidata Solutions by 1.5% in the first quarter. Securian Asset Management Inc now owns 7,587 shares of the company’s stock worth $556,000 after purchasing an additional 113 shares in the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
See Also: How to identify percentage decliners
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.